Selagine, Grifols agree to develop, commercialise immunoglobulin eye drops
Selagine has signed a research, development and sublicense agreement with Grifols for the development and commercialisation of immunoglobulin eye drops for dry eye disease.
Selagine has signed a research, development and sublicense agreement with Grifols for the development and commercialisation of immunoglobulin eye drops for dry eye disease.
Exegenesis Bio has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for gene therapy EXG102-031.
Avista Therapeutics has announced partnership with Roche to develop new AAV gene therapy vectors for the eyes.
Aurion Biotech has raised $120m from biotech and ophthalmology investors to progress its cell therapy programme for corneal edema secondary to endothelial dysfunction.